This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT01557400
First received: March 15, 2012
Last updated: September 18, 2017
Last verified: September 2017
  Purpose
Duchenne/Becker muscular dystrophy (DBMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of DBMD in approximately 10-15% of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study comprises a Phase 3, open-label study of ataluren in patients with nmDBMD who previously received ataluren at an investigator site in a prior PTC-sponsored clinical study. A separate open-label study (PTC124-GD-016-DMD) is being conducted for nmDBMD patients who previously received ataluren at an investigator site in the United States (US).

Condition Intervention Phase
Duchenne Muscular Dystrophy Becker Muscular Dystrophy Dystrophinopathy Drug: Ataluren Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

Resource links provided by NLM:


Further study details as provided by PTC Therapeutics:

Primary Outcome Measures:
  • Long term Safety and Tolerability of Ataluren. [ Time Frame: 336 weeks ]
    The primary objective of this study is to assess the long-term safety and tolerability of 10, 10, 20 mg/kg ataluren in patients with nmDBMD who had prior exposure to ataluren in a PTC-sponsored clinical trial.Safety profile characterized by type, frequency, severity, timing, and relationship to Ataluren of any adverse events or laboratory abnormalities.


Enrollment: 95
Study Start Date: May 2012
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ataluren
Ataluren
Drug: Ataluren
Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
Other Name: PTC124

Detailed Description:

All participating sites must have had at least 1 patient that received ataluren treatment in a prior PTC-sponsored clinical study in DBMD. It is planned that up to ~96 patients will be enrolled.

Subjects will receive ataluren 3 times per day (TID) at respective morning, midday, and evening doses of 10 mg/kg, 10 mg/kg, and 20 mg/kg, for approximately 336 weeks. Study assessments will be performed at clinic visits during screening, on the first day of ataluren dosing, and then every48 weeks during the ataluren treatment period, except for weight, which will be measured every 24 weeks at a primary care physician (PCP). No measures of efficacy will be captured.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
  1. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.

    Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible Institutional Review Board/Independent Ethics Committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the subject should be followed.

  2. History of exposure to ataluren in a prior PTC study in nmDBMD . Note: Patients are considered eligible only if they received ataluren during their participation in one or more prior PTC-sponsored studies of ataluren in nmDBMD. Note: Subjects who have participated in a prior or ongoing PTC study with ataluren in nmDBMD at a trial site in the US or Canada, but reside outside of the US and Canada, may be eligible for this study (with the approval of the PTC Therapeutics Medical Monitor).
  3. Male sex.
  4. In patients who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during ataluren administration and the 6-week follow-up period.
  5. Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions. Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.

Exclusion Criteria:

  1. Exposure to another investigational drug within 1 month prior to start of study treatment.
  2. Eligibility for another ataluren clinical trial that is actively enrolling study participants.
  3. Known hypersensitivity to any of the ingredients or excipients of ataluren (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127 [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, Cab-O-Sil® M5P [colloidal silica], magnesium stearate).
  4. Ongoing use of the following medications:

    1. Coumarin-based anticoagulants (eg, warfarin), phenytoin, tolbutamide, or paclitaxel.
    2. Systemic aminoglycoside therapy
  5. Ongoing uncontrolled medical/surgical condition, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient or make it unlikely that follow-up would be completed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01557400

Locations
Australia, Melbourne
Royal Children's Hospital
Parkville, Melbourne, Australia
Australia
Institute For Neuromuscular Research, The Children's Hospital at Westmead
Westmead, Australia
Belgium
University Hospital KU Leuven
Leuven, Belgium
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada
Canada, British Columbia
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Canada, Ontario
Children's Hospital of Western Ontario
London, Ontario, Canada
France
Hôpital d'Enfants CHU Timone
Marseille, France
Laboratoire d'Exploration Fonctionnelles
Nantes, France
Groupe Hospitalier La Pitie-Salpetriere
Paris, France
Germany
University of Essen - Clinic for Children
Essen, Germany
University Hospital
Freiburg, Germany
Israel
Hadassah Medical Center, Hebrew University Hospital
Jerusalem, Israel
Italy
Ospedale Maggiore Policlinico in Milan
Milan, Italy
Ospedale Pediatrico Bambino Gesu
Rome, Italy
U.O. Complessa di Neuropsichiatria Infantile
Rome, Italy
Spain
Hospital Sant Joan de déu
Barcelona, Spain
Hospital Universitari La Fe
Valencia, Spain
Sweden
Queen Silvia Children's Hospital
Göteborg, Sweden
Astrid Lindgren Pediatric Hospital
Stockholm, Sweden
United Kingdom
Great Ormond Street Hospital
London, United Kingdom
University of Newcastle Institute of Human Genetics
Newcastle Upon Tyne, United Kingdom
Sponsors and Collaborators
PTC Therapeutics
Investigators
Study Director: Edward O'Mara, MD PTC Therapeutics
  More Information

Publications:
Responsible Party: PTC Therapeutics
ClinicalTrials.gov Identifier: NCT01557400     History of Changes
Other Study ID Numbers: PTC124-GD-019-DMD
Study First Received: March 15, 2012
Last Updated: September 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by PTC Therapeutics:
Duchenne muscular dystrophy
Becker muscular dystrophy
Nonsense mutation
Premature stop codon
DMD
BMD
nmDBMD
DBMD
Ataluren
PTC124

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on September 21, 2017